Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 4;2(2):53-6.
doi: 10.1016/S2049-0801(13)70037-2. eCollection 2013.

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

Michael W Shea  1
Affiliations
Review

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

Michael W Shea. Ann Med Surg (Lond). .

Abstract

Neisseria meningitidis infection can cause life-threatening meningitis and meningococcal septicaemia. Over the past 40 years, vaccines against most of the main meningococcal serogroups have offered increasingly good protection from disease, with one major exception in the developed world: serogroup B meningococcus (MenB). In the United States, MenB accounts for about a quarter of cases of meningococcal meningitis, with the bulk of the rest caused by meningococcus serogroups C (MenC) and Y (MenY). In the UK, where a vaccine against MenC is widely used, MenB is now responsible for nearly 90% of cases of invasive meningococcal disease. Recent attempts to create a universal MenB vaccine have been thwarted by the variability of the surface proteins of MenB and by the similarity of the MenB capsule to human glycoproteins. This review discusses current meningococcal vaccine strategies and their limitations with regard to MenB, and examines a promising new strategy for the rational design of a MenB vaccine. Thanks to a fusion of a rational reverse genetics approach and a membrane vesicle approach, a MenB vaccine, 4CMenB (Bexsero(®)), has finally gained regulatory approval in Europe and could be in clinical use by the end of 2013.

Keywords: Evidence Based Medicine; Mass Media; Misrepresentation; Randomised Controlled Trials.

PubMed Disclaimer

References

    1. Schwartz B., Moore P.S., Broome C.V. Global epidemiology of meningococcal disease. Clin Microbiol Rev. 1989;2(Suppl 29):S118–S124. - PMC - PubMed
    1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63. - PubMed
    1. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326. - PMC - PubMed
    1. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human Immunity to the Meningococcus II. Development of Natural Immunity. J Exp Med. 1969;129(6):1327–1348. - PMC - PubMed
    1. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine. 2005;23(17-18):2222–2227. - PubMed